Genetic Alteration Patterns and Clinical Outcomes of Elderly and Secondary Acute Myeloid Leukemia

Overview

Journal Hematol Oncol

Specialties Hematology
Oncology

Date 2019 Jul 27

PMID 31348835

Citations 11

Authors

Shi-Yang Wang

Wen-Yan Cheng

Yuan-Fei Mao

Yong-Mei Zhu

Fu-Jia Liu

Ting-Ting Ma

Yang Shen

Affiliations

Soon will be listed here.

Abstract

To illustrate the clinical and genetic features of elderly and secondary acute myeloid leukemia (AML) patients, we compared 145 elderly AML (e-AML) and 55 secondary AML (s-AML) patients with 451 young de novo AML patients. Both e-AML and s-AML patients showed lower white blood cell (WBC) and bone marrow (BM) blasts at diagnosis. NPM1, DNMT3A, and IDH2 mutations were more common while biallelic CEBPA and IDH1 mutations were less seen in e-AML patients. s-AML patients carried a higher frequency of KMT2A-AF9. In treatment response and survival, e/s-AML conferred a lower complete remission (CR) rate and shorter duration of event-free survival (EFS) and overall survival (OS) compared with young patients. In multivariate analysis, s-AML was an independent risk factor for OS but not EFS in the whole cohort. Importantly, intensive therapy tended to improve the survival of e/s-AML patients without increasing the risk of early death, and hematopoietic stem cell transplantation (HSCT) could rescue the prognosis of s-AML, which should be recommended for the treatment of fit patients.

Citing Articles

Allogeneic hematopoietic stem cell transplantation could overcome the poor prognosis of DNMT3ANPM1FLT3-ITD in acute myeloid leukemia: real-world multicenter analysis in China.

Huo W, Shen Y, Huang J, Yang Y, Fan S, Zhao X Front Med. 2024; 19(1):90-100.

PMID: 39643798 DOI: 10.1007/s11684-024-1091-5.

Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression.

Auerbach S, Puka B, Golla U, Chachoua I Life (Basel). 2024; 14(3).

PMID: 38541635 PMC: 10971423. DOI: 10.3390/life14030309.

Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.

Row C, Lechevalier N, Vial J, Mimoun A, Bastie J, Lafon I EJHaem. 2024; 5(1):84-92.

PMID: 38406512 PMC: 10887270. DOI: 10.1002/jha2.822.

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.

Kim M, Kim T, Ahn S, Lee J, Park J, Shin M Korean J Intern Med. 2023; 38(4):534-545.

PMID: 37291838 PMC: 10338247. DOI: 10.3904/kjim.2022.396.

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.

Sargas C, Ayala R, Larrayoz M, Chillon M, Rodriguez-Arboli E, Bilbao C Blood Cancer J. 2023; 13(1):77.

PMID: 37173322 PMC: 10182047. DOI: 10.1038/s41408-023-00835-5.

References

Shen Y, Zhu Y, Fan X, Shi J, Wang Q, Yan X . Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011; 118(20):5593-603. DOI: 10.1182/blood-2011-03-343988. View

Taskesen E, Bullinger L, Corbacioglu A, Sanders M, Erpelinck C, Wouters B . Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2010; 117(8):2469-75. DOI: 10.1182/blood-2010-09-307280. View

Weng X, Shen Y, Sheng Y, Chen B, Wang J, Li J . Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. Blood Cancer J. 2013; 3:e133. PMC: 3763385. DOI: 10.1038/bcj.2013.31. View

Quintas-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S . Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012; 120(24):4840-5. PMC: 3952725. DOI: 10.1182/blood-2012-06-436055. View

Lazarevic V, Horstedt A, Johansson B, Antunovic P, Billstrom R, Derolf A . Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J. 2014; 4:e188. PMC: 3944658. DOI: 10.1038/bcj.2014.10. View

Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W . Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia. 2016; 30(7):1485-92. DOI: 10.1038/leu.2016.65. View

Kantarjian H, Ravandi F, OBrien S, Cortes J, Faderl S, Garcia-Manero G . Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010; 116(22):4422-9. PMC: 4081299. DOI: 10.1182/blood-2010-03-276485. View

Frohling S, Schlenk R, Breitruck J, Benner A, Kreitmeier S, Tobis K . Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002; 100(13):4372-80. DOI: 10.1182/blood-2002-05-1440. View

Cortes J, Heidel F, Hellmann A, Fiedler W, Smith B, Robak T . Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2018; 33(2):379-389. PMC: 6365492. DOI: 10.1038/s41375-018-0312-9. View

10.

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

11.

Park S, Chi H, Cho Y, Jang S, Park C . Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia. Blood Res. 2013; 48(3):185-92. PMC: 3786278. DOI: 10.5045/br.2013.48.3.185. View

12.

Hulegardh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf A . Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2014; 90(3):208-14. DOI: 10.1002/ajh.23908. View

13.

Kayser S, Dohner K, Krauter J, Kohne C, Horst H, Held G . The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2010; 117(7):2137-45. DOI: 10.1182/blood-2010-08-301713. View

14.

Fernandez-Mercado M, Yip B, Pellagatti A, Davies C, Larrayoz M, Kondo T . Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One. 2012; 7(8):e42334. PMC: 3415392. DOI: 10.1371/journal.pone.0042334. View

15.

Kim M, Williams S . Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. Ann Pharmacother. 2018; 52(8):792-800. DOI: 10.1177/1060028018764923. View

16.

Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S . Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-76. PMC: 4342352. DOI: 10.1182/blood-2014-11-610543. View

17.

Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D . Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2008; 113(18):4179-87. DOI: 10.1182/blood-2008-07-172007. View

18.

Appelbaum F, Gundacker H, Head D, Slovak M, Willman C, Godwin J . Age and acute myeloid leukemia. Blood. 2006; 107(9):3481-5. PMC: 1895766. DOI: 10.1182/blood-2005-09-3724. View

19.

Ostgard L, Medeiros B, Sengelov H, Norgaard M, Klarskov Andersen M, Dufva I . Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol. 2015; 33(31):3641-9. DOI: 10.1200/JCO.2014.60.0890. View

20.

Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74. PMC: 3767041. DOI: 10.1056/NEJMoa1301689. View